BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The study would enrolled a total of 2100 AMI patients undergoing PCI to one of three
antithrombotic regimens: bivalirudin alone, or unfractionated heparin alone, or
unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor.
All enrolled patients would be followed-up to 30 days, 6 months, and 1 year. The purpose of
the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES.